Loading clinical trials...
Loading clinical trials...
The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Oxford BioMedica
NCT05803785 · Age-Related Macular Degeneration
NCT07392255 · Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07440225 · Macular Degeneration, Age-Related Macular Degeneration, and more
NCT05407636 · AMD, nAMD, and more
NCT07308639 · Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
University of Iowa Hospitals & Clinics
Iowa City, Iowa
John Hopkins University Hospital
Baltimore, Maryland
Oregon Health & Science University
Portland, Oregon
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions